RxDoctor Payments Data

Mary D Amico, APRN

Adult Health · Danielson, CTNPI 1710312533

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.2% of the total across 629 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 57 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,022in general payments, 2019–2025

Across 629 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • AstraZeneca$885
  • Lilly USA, LLC$766
  • Amgen$623
  • GSK$479
  • plus $5K from 51 others

What the payments were for

  • Food & beverage$10,92899%
  • Education$931%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie124$1,803
Novo Nordisk68$1,101
AstraZeneca49$885
Lilly USA, LLC39$766
Amgen43$623
GSK27$479
Lundbeck LLC23$369
Sanofi-aventis U.S. LLC20$364
Boehringer Ingelheim15$344
Otsuka America Pharmaceutical, Inc.16$325
Vanda Pharmaceuticals Inc.13$275
Exact Sciences13$266
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)12$239
Johnson & Johnson13$229
Merck11$182
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC9$165
Idorsia Pharmaceuticals US Inc9$154
Pfizer10$151
E.r. Squibb & Sons, L.L.C.7$141
Biohaven Pharmaceutical Holding Company Ltd.8$139
Sunovion Pharmaceuticals Inc.8$129
Takeda Pharmaceuticals U.S.A., Inc.7$121
Astellas Pharma US Inc4$110
Eisai Inc.6$105
Kowa Pharmaceuticals America, Inc.7$104
Corcept Therapeutics4$103
Amarin Pharma, Inc.7$100
Teva Pharmaceuticals USA, Inc.4$96
Novartis4$95
Scilex Pharmaceuticals Inc.4$91
Bayer5$83
Sumitomo Pharma America, Inc.4$69
Resmed Corp1$66
Ardelyx, Inc.3$65
Neurocrine Biosciences, Inc.3$60
Almatica Pharma LLC2$53
Actelion Pharmaceuticals US, Inc.2$50
Soleno Therapeutics, Inc.2$44
Corium, LLC2$44
Cequr Corporation1$42
Bausch Health US, LLC2$41
Insightec,inc1$35
Evoke Pharma, Inc.2$32
Radius Health, Inc.2$32
Optinose US, Inc.1$29
Biohaven Pharmaceuticals, Inc.1$26
Indivior Inc.1$24
Antares Pharma, Inc.1$23
Collegium Pharmaceutical, Inc.1$23
Otsuka Pharmaceutical Development & Commercialization, Inc.1$19
Boston Scientific1$18
Adlon Therapeutics L.p.1$16
Inspire Medical Systems, Inc.1$16
Paratek Pharmaceuticals, Inc.1$16
Shield Therapeutics Inc1$15
Currax Pharmaceuticals LLC1$14
Mylan Specialty L.p.1$13

How this compares

$11,022 in reported general payments places this provider in the 95th percentile of 418 adult health providers in Connecticut.

See all adult health providers in Connecticut

Medicare billing

Part B allowed, 2024
$29,370
Medicare patients
114
Services billed
390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban22$30,497
OzempicSemaglutide27$27,406
JardianceEmpagliflozin12$19,322
XareltoRivaroxaban22$13,544
Pantoprazole Sodium53$2,146
Omeprazole66$1,308
Pregabalin17$994
Gabapentin67$979
Levothyroxine Sodium90$800
Albuterol Sulfate HfaAlbuterol Sulfate41$742
Atorvastatin Calcium97$717
ValacyclovirValacyclovir Hcl11$671
Lisinopril93$654
Metoprolol Succinate66$594
Amlodipine Besylate71$505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$151$30,49722 claims
Novo NordiskOzempic$1,101$27,40627 claims
Boehringer IngelheimJardiance$344$19,32212 claims
Johnson & JohnsonXarelto$229$13,54422 claims
Almatica Pharma LLCSertraline Hcl$53$38160 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 418 adult health providers in Connecticut.

Other adult health in Danielson

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →